University Of California, San Francisco

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Long-term Cardiac Monitoring After Cryptogenic Stroke (CMACS)

Not Applicable

Completed

Conditions: Stroke

Interventions: Device: Cardionet Mobile Cardiac Outpatient Telemetry (MCOT)

First Posted Date: 2009-07-03

Last Posted Date: 2015-02-27

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 40

Registration Number: NCT00932425

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Endothelial Cell Loss After Cataract Surgery

Phase 2

Terminated

Conditions: Cataracts

Interventions: Procedure: Standard phacoemulsification
Procedure: Reduced ultrasound phacoemulsification

First Posted Date: 2009-07-03

Last Posted Date: 2014-08-25

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 39

Registration Number: NCT00932191

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

Integration of HIV Care and Treatment Into Antenatal Care in Migori District, Kenya

Not Applicable

Completed

Conditions: HIV Infections

Interventions: Procedure: Integrated ANC, PMTCT, HIV services

First Posted Date: 2009-07-02

Last Posted Date: 2012-04-10

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 1172

Registration Number: NCT00931216

Locations: 🇰🇪
Migori District Hospital, Migori, Kenya

Hydrogel Patch for the Treatment of Eczema

Not Applicable

Terminated

Conditions: Eczema

Interventions: Device: hydrogel patch
Drug: Triamcinolone (TAC) 0.1% cream

First Posted Date: 2009-06-19

Last Posted Date: 2014-01-31

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 23

Registration Number: NCT00924508

Locations: 🇺🇸
UCSF Psoriasis Skin and Treatment Center, San Francisco, California, United States

Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis

Phase 4

Terminated

Conditions: Plaque Psoriasis
Psoriasis Vulgaris

Interventions: Drug: Taclonex Ointment and Hydrogel Patch
Drug: Taclonex Ointment

First Posted Date: 2009-06-19

Last Posted Date: 2019-04-18

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 35

Registration Number: NCT00924950

Locations: 🇺🇸
UCSF Psoriasis Skin and Treatment Center, San Francisco, California, United States

Impedance Cardiography: Clinical Evaluation of Endotracheal Cardiac Output Monitor (ECOM)

Phase 2

Completed

Conditions: Cardiac Output

Interventions: Device: Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery

First Posted Date: 2009-06-19

Last Posted Date: 2023-11-28

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 261

Registration Number: NCT00924482

Analysis of Blood-based Biomarkers of Asthma

Completed

Conditions: Asthma

First Posted Date: 2009-06-10

Last Posted Date: 2020-08-20

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 127

Registration Number: NCT00917787

Locations: 🇺🇸
UCSF Airway Clinical Research Center, San Francisco, California, United States

Hemangioma Growth During the First 6 Months of Life

Completed

Conditions: Hemangiomas of Infancy

Interventions: Other: No intervention

First Posted Date: 2009-06-02

Last Posted Date: 2013-02-05

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 36

Registration Number: NCT00911781

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States

Pilot Study of a Catheter-based Ultrasound Hyperthermia System

Not Applicable

Terminated

Conditions: Prostate Cancer
Cervical Cancer

Interventions: Procedure: Hyperthermia
Radiation: HDR brachytherapy

First Posted Date: 2009-06-01

Last Posted Date: 2021-07-07

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 13

Registration Number: NCT00911079

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Biological: HSPPC-96
Drug: Temozolomide
Procedure: Standard Surgical Resection

First Posted Date: 2009-05-20

Last Posted Date: 2021-03-24

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 70

Registration Number: NCT00905060

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy